• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2024 Jul;18(7):e13339.
doi: 10.1111/irv.13339. Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022

Ryan Sandford[SUP] 1 2 3 [/SUP], Ruchi Yadav[SUP] 1 [/SUP], Emma K Noble[SUP] 1 2 [/SUP], Kelsey Sumner[SUP] 1 [/SUP], Devyani Joshi[SUP] 1 [/SUP], Sara Y Tartof[SUP] 4 5 [/SUP], Karen J Wernli[SUP] 6 [/SUP], Emily T Martin[SUP] 7 [/SUP], Manjusha Gaglani[SUP] 8 9 [/SUP], Richard K Zimmerman[SUP] 10 [/SUP], H Keipp Talbot[SUP] 11 [/SUP], Carlos G Grijalva[SUP] 11 [/SUP], Edward A Belongia[SUP] 12 [/SUP], Christina Carlson[SUP] 1 [/SUP], Melissa Coughlin[SUP] 1 [/SUP], Brendan Flannery[SUP] 1 [/SUP], Brad Pearce[SUP] 3 [/SUP], Eric Rogier[SUP] 1 [/SUP]



Affiliations
Abstract

We describe humoral immune responses in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS-CoV-2 infection.

Keywords: COVID‐19; Omicron subvariants; SARS‐CoV‐2 infection; immune response.

 
Back
Top Bottom